RARE FY2025 EPS Estimate Decreased by Cantor Fitzgerald

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) – Investment analysts at Cantor Fitzgerald lowered their FY2025 earnings per share estimates for Ultragenyx Pharmaceutical in a note issued to investors on Wednesday, May 7th. Cantor Fitzgerald analyst K. Kluska now anticipates that the biopharmaceutical company will post earnings per share of ($5.08) for the year, down from their prior forecast of ($4.99). Cantor Fitzgerald currently has a “Overweight” rating and a $118.00 target price on the stock. The consensus estimate for Ultragenyx Pharmaceutical’s current full-year earnings is ($5.18) per share.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($1.57) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.03). Ultragenyx Pharmaceutical had a negative net margin of 101.60% and a negative return on equity of 193.80%. The company had revenue of $139.29 million during the quarter, compared to the consensus estimate of $145.98 million. During the same period in the previous year, the firm posted ($2.03) EPS. The business’s quarterly revenue was up 28.0% compared to the same quarter last year.

RARE has been the subject of a number of other reports. Piper Sandler decreased their price objective on Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an “overweight” rating for the company in a report on Monday, March 17th. Canaccord Genuity Group raised their price target on shares of Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the stock a “buy” rating in a research note on Tuesday, February 18th. Wedbush reissued a “neutral” rating and issued a $48.00 price objective (up previously from $46.00) on shares of Ultragenyx Pharmaceutical in a research report on Monday, January 13th. HC Wainwright reaffirmed a “buy” rating and issued a $95.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Friday, February 14th. Finally, Morgan Stanley boosted their price target on shares of Ultragenyx Pharmaceutical from $64.00 to $65.00 and gave the stock an “overweight” rating in a research report on Friday. One investment analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the company. According to data from MarketBeat, Ultragenyx Pharmaceutical presently has an average rating of “Moderate Buy” and an average target price of $90.93.

Ultragenyx Pharmaceutical Trading Down 2.3 %

Shares of NASDAQ RARE opened at $35.16 on Friday. The company has a fifty day moving average price of $36.89 and a 200 day moving average price of $42.55. The firm has a market cap of $3.30 billion, a PE ratio of -5.55 and a beta of 0.34. Ultragenyx Pharmaceutical has a 1-year low of $29.59 and a 1-year high of $60.37.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

Large investors have recently added to or reduced their stakes in the stock. California State Teachers Retirement System boosted its stake in shares of Ultragenyx Pharmaceutical by 0.3% during the fourth quarter. California State Teachers Retirement System now owns 78,051 shares of the biopharmaceutical company’s stock valued at $3,284,000 after purchasing an additional 268 shares in the last quarter. Van ECK Associates Corp boosted its position in Ultragenyx Pharmaceutical by 18.4% during the 4th quarter. Van ECK Associates Corp now owns 1,760 shares of the biopharmaceutical company’s stock worth $74,000 after buying an additional 273 shares during the period. Wealth Enhancement Advisory Services LLC grew its holdings in Ultragenyx Pharmaceutical by 1.4% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 22,047 shares of the biopharmaceutical company’s stock worth $928,000 after acquiring an additional 294 shares during the last quarter. GAMMA Investing LLC increased its position in Ultragenyx Pharmaceutical by 76.2% in the 1st quarter. GAMMA Investing LLC now owns 747 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 323 shares during the period. Finally, Xponance Inc. raised its stake in shares of Ultragenyx Pharmaceutical by 2.8% during the first quarter. Xponance Inc. now owns 12,552 shares of the biopharmaceutical company’s stock valued at $455,000 after acquiring an additional 347 shares during the last quarter. Institutional investors and hedge funds own 97.67% of the company’s stock.

Insider Buying and Selling

In other Ultragenyx Pharmaceutical news, EVP Thomas Richard Kassberg sold 6,028 shares of the business’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $42.10, for a total value of $253,778.80. Following the completion of the sale, the executive vice president now owns 265,238 shares of the company’s stock, valued at $11,166,519.80. The trade was a 2.22 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Karah Herdman Parschauer sold 2,990 shares of the firm’s stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $42.88, for a total transaction of $128,211.20. Following the transaction, the executive vice president now directly owns 54,991 shares in the company, valued at $2,358,014.08. This represents a 5.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 125,405 shares of company stock valued at $5,285,169. Company insiders own 5.50% of the company’s stock.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.